BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk
Tirzepatide, produkta foto

8 laboratorijas ziņojumi

PDF
99%
Tīrība
Pārbaudīts
Tirzepatide 10mg
Laboratorija
Analiza Białek
Datums
November 2026
Rezultāts
99% purity (10.88 mg measured)
Endotoksīni
5.99 EU/vial
Pasūtījuma nr.
Parole

Neatkarīgi pārbaudīts, ar paroli pārbaudāms tieši laboratorijā.

GLP-1

Tirzepatide

GLP-1

Pasūtījums

Vienības cena - Bezmaksas piegāde Vācijā no 200 € Black Weeks laikā
  • DHL ar izsekošanu
  • Diskrēts iepakojums

4.6 no 5 Trustpilot73 atsauksmes

Meklēts arī kā: Tirzepatid · Tirze · LY3298176

Īsumā

Tirzepatide skaitļos

Galvenie rādītāji no mūsu leksikona. Velciet punktu pa līkni, lai redzētu, cik daudz paliek pēc vienas devas, pēc aprēķina.

Pilns leksikona ieraksts

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~5 days

Half-life ~5 days
After 10 days: 25 %
Day 550 %Day 7, next dose38 %Day 1025 %Day 1512.5 %Day 253.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

~5days

Class
Dual GIP / GLP-1 agonist
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 120 mg10 sizes in the shop

Zināšanas

Viss par Tirzepatide

Noderēs

Kas jums vēl būs vajadzīgs

Bakteriostatiskais ūdens tiek automātiski pievienots grozam. Šļirces un salvetes - ar vienu klikšķi.

Insulīna šļirces

10 gab. · 5.50 €

Spirta salvetes

50 gab. · 10 €

Cik daudz ūdens?

Vienības uz šļirces jūsu flakona izmēram.

Atvērt kalkulatoru →

FAQ

Bieži uzdotie jautājumi

Avoti katrai atbildei: leksikona ieraksts

Vēl ir jautājums?

Rakstiet mums, mūsu komanda jums palīdzēs.

Is Tirzepatide approved?

Yes. The first approval came in May 2022 in the USA for type 2 diabetes, the European Medicines Agency issued a positive opinion shortly after. ChEMBL now lists type 2 diabetes, obesity and overweight as approved indications. The information here describes the state of research and is not a recommendation for use.

How does Tirzepatide differ from Semaglutide and Retatrutide?

The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GIP and GLP-1, Retatrutide also on the glucagon receptor. In a head-to-head trial against semaglutide (SURMOUNT-5) weight fell by 20.2 versus 13.7 percent after 72 weeks. A comparison with Retatrutide is still running (TRIUMPH-5, planned end November 2026).

What did the phase 3 trials show?

In SURMOUNT-1 (obesity without diabetes) weight fell by 20.9 percent on average after 72 weeks at the highest study dose, by 3.1 percent on placebo. In SURMOUNT-2 (with type 2 diabetes) it was 14.7 versus 3.2 percent. In SURPASS-1 long-term blood sugar (HbA1c) fell by up to 2.07 percentage points in 40 weeks, on placebo it rose slightly.

How long does Tirzepatide stay in the body?

The half-life in the first human study was about five days (116.7 hours on average). A fatty acid attached to the molecule makes this possible: it lets the molecule bind to the blood protein albumin. That fits one dose a week, which is how the trials give it.

What happens after stopping?

SURMOUNT-4 tested this. After 36 weeks of Tirzepatide everyone had lost 20.9 percent on average. Those switched to placebo regained 14.0 percent on average by week 88. Those who continued lost a further 5.5 percent. Over the whole period it was 25.3 versus 9.9 percent.

Which side effects were seen?

Most often gastrointestinal effects such as nausea, diarrhoea and vomiting, mostly mild to moderate and mainly while the dose was being increased. In SURMOUNT-1 4.3 to 7.1 percent stopped because of side effects depending on the dose, 2.6 percent on placebo. A phase 2 trial showed that a lower start and smaller steps went along with fewer complaints.

What is known about heart, liver and sleep apnoea?

In SUMMIT (heart failure with preserved ejection fraction and obesity) 9.9 percent had cardiovascular death or worsening heart failure, 15.3 percent on placebo. In SURPASS-CVOT Tirzepatide was not worse than dulaglutide for cardiovascular events. In SYNERGY-NASH MASH resolved in 62 percent at the highest study dose, in 10 percent on placebo. In sleep apnoea the number of breathing pauses per hour fell by 25.3 in one of the two trials, by 5.3 on placebo.

Which trials are still running?

Six of the listed phase 3 trials are not finished yet. The largest is SURMOUNT-MMO on morbidity and mortality in obesity with 15,374 participants (planned end October 2027). There are also trials in type 1 diabetes, in adolescents and in children aged 6 to 11.

Salīdzinājumi

Kā tas atšķiras

Saistītie

Saistītie produkti